Answers are grounded in this paper and cite their sources.
In 2002, 39% of HIV cases in the United Kingdom (1735/4419) were acquired in Africa [1]. A recent case from sub-Saharan Africa seen at St Mary's Hospital, Portsmouth, demonstrated several challenges for clinicians managing these patients in the UK. In March 2002, a 40-year-old Zimbabwean sales representative attended our department requesting an HIV antibody test. He had been in the UK for one week and reported a 6-month history of night sweats, an intermittent skin rash and extreme tiredness. HIV infection was confirmed positive by AXSYM (Abbott, Maidenhead, UK) and Vidas Duo (BioMerieux, Basingstoke, UK). He had a CD4 cell count of 30 cells/mm3 and a plasma viral load of 111 000 copies/ml (log 5.05). A plasma sample was sent for genotypic resistance testing. The patient reported that he was not surprised that he had HIV infection, because although he had not previously had an HIV antibody test, a CD4 cell count test taken in Zimbabwe ‘had been low'. He then admitted to taking antiretroviral therapy (ART), comprising indinavir, stavudine and didanosine, for a 4-month period from October 2001 until one week before his arrival in the UK. Resistance testing suggested multiple nucleoside drug resistance; K65R, V75I, F77L, Y115F, F116Y and Q151M. Mutations at K20R, L24I, M36I, and V82A also suggested protease inhibitor resistance. On further questioning, the patient later admitted that he had also briefly taken some Combivir tablets (zidovudine/lamivudine) in September 2001 while in Zimbabwe, but had switched to the other drugs when he could no longer obtain Combivir. He was started on highly active antiretroviral therapy (HAART) with tenofovir, lopinavir, didanosine and nevirapine. Initially he had a symptomatic improvement associated with a reduction in the plasma viral load to 2110 copies/ml and a CD4 cell count of 300 cells/mm3. However, despite reported good adherence to medication, his plasma viral load did not reach an undetectable level by 16 weeks of treatment. A further genotypic resistance profile performed in August 2002 showed a similar resistance pattern to the previous sample and new mutations at Y181C, L10I, M46I and I54V, suggesting resistance to the non-nucleoside reverse transcriptase inhibitor nevirapine, and further protease inhibitor resistance. While waiting for these results, the patient's visa expired and he returned to Zimbabwe. HIV-infected African patients in the United Kingdom have been reported to have a good response to HAART [2,3]. As a result of previous inadequate and intermittent therapy, this man unexpectedly demonstrated widespread HAART resistance that is more typical of a patient who has received ART over many years. His previous and current adherence with treatment was difficult to ascertain. Clinicians managing HIV infection in clinics where HAART and HIV monitoring are readily available should not assume that HIV-infected patients presenting from sub-Saharan Africa are antiretroviral naive. Access to anti-HIV drugs through drug access initiatives is slowly being introduced in resource-poor settings. However, antiretroviral agents are already available in many sub-Saharan African countries via local pharmacies, private clinics or friends or family. Under these circumstances they may be given with little explanation of therapy or monitoring of adherence and treatment response. Patients from this region may, therefore, have been taking sub-optimal and intermittent therapy, depending on treatment availability and financial constraints. Once in a country where HAART is readily available, they may be reluctant to admit to previous treatment for a variety of reasons, including fear of stigma and lack of understanding about the significance of previous ART exposure. Resistance to ART in sub-Saharan Africa has already been documented in several countries, suggesting that there could be a rapid emergence of resistant strains from this region [4,5]. The public health implications of this are significant. Currently, in the Genitourinary Medicine Department in Portsmouth, of the 40 new cases of HIV registered in 2002, 58% were acquired in sub-Saharan Africa. The transmission of drug-resistant strains arising from heterosexual transmission from African patients in Europe needs to be minimized by reinforcing messages to improve the understanding of the importance of adherence with therapy and education to limit further sexual transmission. This case also highlights the importance of resistance testing at baseline, even for patients in whom resistance may not be suspected. In the long term, uncontrolled, previous exposure to ART in sub-Saharan Africa means that it may potentially be difficult to treat many patients effectively by the time such treatment becomes widely available in the continent.
No takes yet. Share an insight, caveat, or question.
Foley et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: